Market Currents
Optimer Pharmaceuticals (OPTR) is up 6.4% after Jefferies reiterates a Buy and $17 PT. The firm...
-
Monday, September 19, 2011, 2:34 PM ETOptimer Pharmaceuticals (OPTR) is up 6.4% after Jefferies reiterates a Buy and $17 PT. The firm is bullish on better-than-expected sales of Optimer's Dificid drug, and on the pending EU launch of the drug by partner Astellas (ALPMY.PK). Jefferies also thinks milestone payment from Astellas will strengthen Optimer's cash position.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
